Home LiteratureArticle Details
PMID: 25753580 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Review

The interaction of anticancer therapies with tumor-associated macrophages.

The Journal of experimental medicine ·Vol. 212 ·No. 4 ·2015-04-06 ·Pages 435-45

Mantovani A, Allavena P

Abstract

Macrophages are essential components of the inflammatory microenvironment of tumors. Conventional treatment modalities (chemotherapy and radiotherapy), targeted drugs, antiangiogenic agents, and immunotherapy, including checkpoint blockade, all profoundly influence or depend on the function of tumor-associated macrophages (TAMs). Chemotherapy and radiotherapy can have dual influences on TAMs in that a misdirected macrophage-orchestrated tissue repair response can result in chemoresistance, but in other circumstances, TAMs are essential for effective therapy. A better understanding of the interaction of anticancer therapies with innate immunity, and TAMs in particular, may pave the way to better patient selection and innovative combinations of conventional approaches with immunotherapy.

MeSH Terms
Animals Drug Resistance, Neoplasm/immunology Humans Immunotherapy/methods Macrophages/immunology,pathology Neoplasms/immunology,pathology,therapy Tumor Microenvironment/immunology
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Mantovani Alberto
A. Mantovani and P. Allavena are at the IRCCS Humanitas Clinical and Research Center and Humanitas University, 20089 Rozzano, Milano, Italy alberto.mantovani@humanitasresearch.it paola.allavena@humanitasresearch.it.
Allavena Paola
A. Mantovani and P. Allavena are at the IRCCS Humanitas Clinical and Research Center and Humanitas University, 20089 Rozzano, Milano, Italy alberto.mantovani@humanitasresearch.it paola.allavena@humanitasresearch.it.
References (100)
100 references, click to expand
  1. Latent enhancers activated by stimulation in differentiated cells.
    Cell. 2013 Jan 17;152(1-2):157-71 PMID: 23332752
  2. Neutralizing tumor-promoting chronic inflammation: a magic bullet?
    Science. 2013 Jan 18;339(6117):286-91 PMID: 23329041
  3. Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells.
    Cancer Immunol Res. 2013 Jul;1(1):32-42 PMID: 24777248
  4. The origin and function of tumor-associated macrophages.
    Immunol Today. 1992 Jul;13(7):265-70 PMID: 1388654
  5. Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth.
    Nat Med. 2013 Jan;19(1):57-64 PMID: 23202296
  6. Sensitizing protective tumor microenvironments to antibody-mediated therapy.
    Cell. 2014 Jan 30;156(3):590-602 PMID: 24485462
  7. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm.
    Nat Immunol. 2010 Oct;11(10):889-96 PMID: 20856220
  8. Macrophage plasticity and polarization: in vivo veritas.
    J Clin Invest. 2012 Mar;122(3):787-95 PMID: 22378047
  9. Immunologically augmented cancer treatment using modern radiotherapy.
    Trends Mol Med. 2013 Sep;19(9):565-82 PMID: 23831337
  10. Tumor-associated macrophages regulate tumorigenicity and anticancer drug responses of cancer stem/initiating cells.
    Proc Natl Acad Sci U S A. 2011 Jul 26;108(30):12425-30 PMID: 21746895
  11. Impeding macrophage entry into hypoxic tumor areas by Sema3A/Nrp1 signaling blockade inhibits angiogenesis and restores antitumor immunity.
    Cancer Cell. 2013 Dec 9;24(6):695-709 PMID: 24332039
  12. Tracking of intertissue migration reveals the origins of tumor-infiltrating monocytes.
    Proc Natl Acad Sci U S A. 2014 May 27;111(21):7771-6 PMID: 24825888
  13. IRF5 promotes inflammatory macrophage polarization and TH1-TH17 responses.
    Nat Immunol. 2011 Mar;12(3):231-8 PMID: 21240265
  14. HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF.
    Cancer Cell. 2011 Jan 18;19(1):31-44 PMID: 21215706
  15. Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma.
    Neuro Oncol. 2013 Aug;15(8):1079-87 PMID: 23828240
  16. Gata6 regulates aspartoacylase expression in resident peritoneal macrophages and controls their survival.
    J Exp Med. 2014 Jul 28;211(8):1525-31 PMID: 25024137
  17. Functional polarization of tumour-associated macrophages by tumour-derived lactic acid.
    Nature. 2014 Sep 25;513(7519):559-63 PMID: 25043024
  18. The tumor-immune microenvironment and response to radiation therapy.
    J Mammary Gland Biol Neoplasia. 2010 Dec;15(4):411-21 PMID: 21161342
  19. Postsurgical adjuvant tumor therapy by combining anti-angiopoietin-2 and metronomic chemotherapy limits metastatic growth.
    Cancer Cell. 2014 Dec 8;26(6):880-95 PMID: 25490450
  20. Constant replenishment from circulating monocytes maintains the macrophage pool in the intestine of adult mice.
    Nat Immunol. 2014 Oct;15(10):929-37 PMID: 25151491
  21. Coordinated regulation of myeloid cells by tumours.
    Nat Rev Immunol. 2012 Apr;12(4):253-68 PMID: 22437938
  22. Cancer immunotherapy and breaking immune tolerance: new approaches to an old challenge.
    Cancer Res. 2015 Jan 1;75(1):5-10 PMID: 25524899
  23. Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second-look laparotomy.
    J Clin Oncol. 1996 Feb;14(2):343-50 PMID: 8636742
  24. In situ proliferation contributes to accumulation of tumor-associated macrophages in spontaneous mammary tumors.
    Eur J Immunol. 2014 Aug;44(8):2247-62 PMID: 24796276
  25. CSF-1R inhibition alters macrophage polarization and blocks glioma progression.
    Nat Med. 2013 Oct;19(10):1264-72 PMID: 24056773
  26. Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes.
    Cancer Res. 2010 Jul 15;70(14):5728-39 PMID: 20570887
  27. Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy.
    Oncoimmunology. 2014 May 14;3:e28780 PMID: 25083318
  28. Tumor-associated macrophages: from mechanisms to therapy.
    Immunity. 2014 Jul 17;41(1):49-61 PMID: 25035953
  29. Antibody therapeutics in cancer.
    Science. 2013 Sep 13;341(6151):1192-8 PMID: 24031011
  30. Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer.
    Genes Dev. 2011 Dec 1;25(23):2465-79 PMID: 22156207
  31. Anti-vascular endothelial growth factor therapy-induced glioma invasion is associated with accumulation of Tie2-expressing monocytes.
    Oncotarget. 2014 Apr 30;5(8):2208-20 PMID: 24809734
  32. Tissue-specific signals control reversible program of localization and functional polarization of macrophages.
    Cell. 2014 May 8;157(4):832-44 PMID: 24792964
  33. Immunologic correlates of the abscopal effect in a patient with melanoma.
    N Engl J Med. 2012 Mar 8;366(10):925-31 PMID: 22397654
  34. Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells.
    Cancer Cell. 2014 Nov 10;26(5):623-37 PMID: 25446896
  35. Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses.
    Cancer Res. 2013 Feb 1;73(3):1128-41 PMID: 23221383
  36. Hallmarks of cancer: the next generation.
    Cell. 2011 Mar 4;144(5):646-74 PMID: 21376230
  37. KIT oncogene inhibition drives intratumoral macrophage M2 polarization.
    J Exp Med. 2013 Dec 16;210(13):2873-86 PMID: 24323358
  38. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy.
    Cancer Discov. 2011 Jun;1(1):54-67 PMID: 22039576
  39. Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor evasion of antiangiogenic therapy.
    Blood. 2010 Feb 18;115(7):1461-71 PMID: 20008303
  40. Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer.
    Invest New Drugs. 2013 Jun;31(3):760-8 PMID: 22907596
  41. PTX3 is an extrinsic oncosuppressor regulating complement-dependent inflammation in cancer.
    Cell. 2015 Feb 12;160(4):700-14 PMID: 25679762
  42. The chemokine system, and its CCR5 and CXCR4 receptors, as potential targets for personalized therapy in cancer.
    Cancer Lett. 2014 Sep 28;352(1):36-53 PMID: 24141062
  43. CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer.
    Cancer Res. 2013 May 1;73(9):2782-94 PMID: 23418320
  44. Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy.
    Cancer Cell. 2014 Jun 16;25(6):846-59 PMID: 24898549
  45. Macrophage plasticity and polarization in tissue repair and remodelling.
    J Pathol. 2013 Jan;229(2):176-85 PMID: 23096265
  46. An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer.
    Cancer Immunol Res. 2013 Dec;1(6):365-72 PMID: 24563870
  47. Tumor hypoxia does not drive differentiation of tumor-associated macrophages but rather fine-tunes the M2-like macrophage population.
    Cancer Res. 2014 Jan 1;74(1):24-30 PMID: 24220244
  48. Macrophage biology in development, homeostasis and disease.
    Nature. 2013 Apr 25;496(7446):445-55 PMID: 23619691
  49. Tissue-resident macrophage enhancer landscapes are shaped by the local microenvironment.
    Cell. 2014 Dec 4;159(6):1312-26 PMID: 25480296
  50. "Re-educating" tumor-associated macrophages by targeting NF-kappaB.
    J Exp Med. 2008 Jun 9;205(6):1261-8 PMID: 18490490
  51. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans.
    Science. 2011 Mar 25;331(6024):1612-6 PMID: 21436454
  52. Autophagy and cellular immune responses.
    Immunity. 2013 Aug 22;39(2):211-27 PMID: 23973220
  53. The transcription factor Gata6 links tissue macrophage phenotype and proliferative renewal.
    Science. 2014 May 9;344(6184):645-8 PMID: 24762537
  54. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment.
    Science. 2013 Nov 22;342(6161):967-70 PMID: 24264989
  55. Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis.
    Nature. 2014 Nov 6;515(7525):130-3 PMID: 25337873
  56. Anti-tumor and immunomodulatory activity of intraperitoneal IFN-gamma in ovarian carcinoma patients with minimal residual tumor after chemotherapy.
    Int J Cancer. 1992 Apr 22;51(1):42-6 PMID: 1563843
  57. Targeting the tumour vasculature: insights from physiological angiogenesis.
    Nat Rev Cancer. 2010 Jul;10(7):505-14 PMID: 20574450
  58. B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma.
    J Exp Med. 2006 Apr 17;203(4):871-81 PMID: 16606666
  59. Progressive replacement of embryo-derived cardiac macrophages with age.
    J Exp Med. 2014 Oct 20;211(11):2151-8 PMID: 25245760
  60. Impact of tumour microenvironment and Fc receptors on the activity of immunomodulatory antibodies.
    Trends Immunol. 2014 Jul;35(7):290-8 PMID: 24953012
  61. The blockade of immune checkpoints in cancer immunotherapy.
    Nat Rev Cancer. 2012 Apr;12(4):252-64 PMID: 22437870
  62. Colony-stimulating factor-1 blockade by antisense oligonucleotides and small interfering RNAs suppresses growth of human mammary tumor xenografts in mice.
    Cancer Res. 2004 Aug 1;64(15):5378-84 PMID: 15289345
  63. Strategies for optimizing the response of cancer and normal tissues to radiation.
    Nat Rev Drug Discov. 2013 Jul;12(7):526-42 PMID: 23812271
  64. Genetic engineering of hematopoiesis for targeted IFN-α delivery inhibits breast cancer progression.
    Sci Transl Med. 2014 Jan 1;6(217):217ra3 PMID: 24382895
  65. Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules.
    Cancer Cell. 2004 May;5(5):429-41 PMID: 15144951
  66. Local macrophage proliferation, rather than recruitment from the blood, is a signature of TH2 inflammation.
    Science. 2011 Jun 10;332(6035):1284-8 PMID: 21566158
  67. The irradiated tumor microenvironment: role of tumor-associated macrophages in vascular recovery.
    Front Physiol. 2013 Jul 17;4:157 PMID: 23882218
  68. A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors.
    Cancer Chemother Pharmacol. 2013 Apr;71(4):1041-50 PMID: 23385782
  69. Macrophages promote the invasion of breast carcinoma cells via a colony-stimulating factor-1/epidermal growth factor paracrine loop.
    Cancer Res. 2005 Jun 15;65(12):5278-83 PMID: 15958574
  70. Immunogenic cell death in cancer therapy.
    Annu Rev Immunol. 2013;31:51-72 PMID: 23157435
  71. Macrophage activation and polarization: nomenclature and experimental guidelines.
    Immunity. 2014 Jul 17;41(1):14-20 PMID: 25035950
  72. Sorafenib perpetuates cellular anticancer effector functions by modulating the crosstalk between macrophages and natural killer cells.
    Hepatology. 2013 Jun;57(6):2358-68 PMID: 23424039
  73. The cellular and molecular origin of tumor-associated macrophages.
    Science. 2014 May 23;344(6186):921-5 PMID: 24812208
  74. PF-03732010: a fully human monoclonal antibody against P-cadherin with antitumor and antimetastatic activity.
    Clin Cancer Res. 2010 Nov 1;16(21):5177-88 PMID: 20829331
  75. Macrophages mediate gemcitabine resistance of pancreatic adenocarcinoma by upregulating cytidine deaminase.
    Oncogene. 2014 Jul 17;33(29):3812-9 PMID: 23995783
  76. Differential macrophage programming in the tumor microenvironment.
    Trends Immunol. 2012 Mar;33(3):119-26 PMID: 22277903
  77. Macrophage regulation of tumor responses to anticancer therapies.
    Cancer Cell. 2013 Mar 18;23(3):277-86 PMID: 23518347
  78. Chemotherapy alters monocyte differentiation to favor generation of cancer-supporting M2 macrophages in the tumor microenvironment.
    Cancer Res. 2013 Apr 15;73(8):2480-92 PMID: 23436796
  79. A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma.
    Clin Cancer Res. 2013 Nov 15;19(22):6286-95 PMID: 23983255
  80. Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death.
    Oncoimmunology. 2014 Apr 25;3:e28518 PMID: 25071979
  81. The histone H3 lysine-27 demethylase Jmjd3 links inflammation to inhibition of polycomb-mediated gene silencing.
    Cell. 2007 Sep 21;130(6):1083-94 PMID: 17825402
  82. Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study.
    Target Oncol. 2015 Mar;10(1):111-23 PMID: 24928772
  83. B cells regulate macrophage phenotype and response to chemotherapy in squamous carcinomas.
    Cancer Cell. 2014 Jun 16;25(6):809-21 PMID: 24909985
  84. Elusive identities and overlapping phenotypes of proangiogenic myeloid cells in tumors.
    Am J Pathol. 2010 Apr;176(4):1564-76 PMID: 20167863
  85. Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T-cell transfer in breast cancer.
    Cancer Res. 2014 Jan 1;74(1):104-18 PMID: 24197130
  86. Role of macrophage targeting in the antitumor activity of trabectedin.
    Cancer Cell. 2013 Feb 11;23(2):249-62 PMID: 23410977
  87. Human dermal CD14⁺ cells are a transient population of monocyte-derived macrophages.
    Immunity. 2014 Sep 18;41(3):465-77 PMID: 25200712
  88. Role of host defense merchanisms in the antitumor activity of adriamycin and daunomycin in mice.
    J Natl Cancer Inst. 1979 Jul;63(1):61-6 PMID: 286835
  89. Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells.
    Cancer Cell. 2011 Apr 12;19(4):512-26 PMID: 21481792
  90. A paracrine circuit in the regulation of the proliferation of macrophages infiltrating murine sarcomas.
    J Immunol. 1990 Mar 15;144(6):2409-12 PMID: 2138198
  91. Colony-stimulating factor-1 antibody reverses chemoresistance in human MCF-7 breast cancer xenografts.
    Cancer Res. 2006 Apr 15;66(8):4349-56 PMID: 16618760
  92. Exploring the full spectrum of macrophage activation.
    Nat Rev Immunol. 2008 Dec;8(12):958-69 PMID: 19029990
  93. Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach.
    Br J Cancer. 2006 Aug 7;95(3):272-81 PMID: 16832418
  94. Cancer-related inflammation.
    Nature. 2008 Jul 24;454(7203):436-44 PMID: 18650914
  95. Environment drives selection and function of enhancers controlling tissue-specific macrophage identities.
    Cell. 2014 Dec 4;159(6):1327-40 PMID: 25480297
  96. Low-dose irradiation programs macrophage differentiation to an iNOS⁺/M1 phenotype that orchestrates effective T cell immunotherapy.
    Cancer Cell. 2013 Nov 11;24(5):589-602 PMID: 24209604
  97. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide.
    Science. 2013 Nov 22;342(6161):971-6 PMID: 24264990
  98. JNJ-28312141, a novel orally active colony-stimulating factor-1 receptor/FMS-related receptor tyrosine kinase-3 receptor tyrosine kinase inhibitor with potential utility in solid tumors, bone metastases, and acute myeloid leukemia.
    Mol Cancer Ther. 2009 Nov;8(11):3151-61 PMID: 19887542
  99. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma.
    J Exp Med. 2013 Aug 26;210(9):1695-710 PMID: 23897981
  100. Role for Spi-C in the development of red pulp macrophages and splenic iron homeostasis.
    Nature. 2009 Jan 15;457(7227):318-21 PMID: 19037245
Article Info
Journal
The Journal of experimental medicine
Abbr.
J Exp Med
ISSN
1540-9538
DOI
10.1084/jem.20150295
Email
alberto.mantovani@humanitasresearch.it
paola.allavena@humanitasresearch.it
Published
2015-04-06
Epub
2015-00-09
Pages
435-45
Language
English
Region
United States
NLM ID
2985109R
PMCID
PMC4387285
Subset
IM
External Links
PubMed source DOI: 10.1084/jem.20150295 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2